Charles Schwab Investment Management Inc. boosted its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 2 ...

Learn more about whether Sarepta Therapeutics, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

Learn more about whether Kymera Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Scotiabank analyst Louise Chen initiated coverage of Sarepta (SRPT) with a Sector Perform rating and $105 price target The firm says that ...

Sarepta Therapeutics hits 52-week lows despite strong earnings and growth. Read why investors should view SRPT as a high risk ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by stock analysts at HC ...

ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...

The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other diseases, such as systematic sclerosis. Duvyzat was approved in March 2024 and ...

Q4 2024 Earnings Call Transcript February 26, 2025 Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.5, expectations were $1.38. Operator: Good afternoon. And welcome to the ...

6. Elevidys for Duchenne muscular dystrophy (DMD) On June 20, 2024, the FDA expanded the approval of Sarepta Therapeutics’ Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy initially ...

Net product revenues soared 75% to $638.2 million compared to the same quarter last year, driven by strong sales of its gene therapy ELEVIDYS. ELEVIDYS, approved in June 2023 for Duchenne muscular ...

Sarepta Therapeutics, Inc. SRPT reported fourth-quarter 2024 earnings per share (EPS) of $1.50, which missed the Zacks Consensus Estimate of $1.87. However, the reported figure was significantly ...